Industry Insights
A Conversation With Professor Josef Penninger on the Journey to a COVID-19 Therapeutic
Industry InsightThe ACE2 receptor has garnered significant attention for the wrong reasons over recent months. Could it point towards an exit route out of this pandemic? In an interview with Technology Networks, the renowned immunologist Professor Josef Penninger explains why he thinks so, and discusses the latest clinical data obtained from testing the soluble ACE2 receptor, APN01.
Read More
LAMP-Based Testing for COVID-19
Industry InsightTechnology Networks recently spoke to Dr Gary Keating, Chief Technical Officer at Hibergene Diagnostics, to learn more about LAMP technology and the advantages it could offer for COVID-19 testing. Gary also discussed some of the challenges faced when developing diagnostics and how the COVID-19 pandemic has impacted diagnostic design and manufacturing.
Read More
From Vaccine Printers to DNA Data Storage, What's in Store for the Future of Synthetic Biology?
Industry InsightScientists are harnessing the power of synthetic biology – a field of science that involves redesigning biological components to generate novel synthetic entities – to solve scientific problems and drive innovation in medicine. Technology Networks recently spoke with Codex DNA’s CEO Todd R. Nelson to learn about the impact synthetic biology techniques are having on pharmaceutical development and the "big trends" in synthetic biology we are already seeing and are expected to see in the next few years.
Read More
Progress in Companion Diagnostic Development for Low-Grade Glioma
Industry InsightTo learn about the benefits of accelerating turnaround times for genomic testing and the importance of partnering with pharma companies to develop companion diagnostics, Technology Networks spoke with Luca Quagliata, PhD, BCMAS, global director of medical affairs for Thermo Fisher Scientific.
Read More
New RNA Extraction Strategies Help Mitigate Shortages in SARS-CoV-2 PCR Components
Industry InsightAs the world continues to battle through the pandemic, developing innovative strategies to expand the availability of extraction, and any other testing components that are facing supply issues, will be an ongoing requirement.
Read More
Biomaterial-Based Vaccine That Sits Under the Skin Shows Promise Against SARS-CoV-2
Industry InsightA team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.
Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation
Industry InsightUp to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.
Read More
CRISPR: Tips and Tricks for Efficient Delivery Into Primary Cells and Cell Lines
Industry InsightThis article provides tips and tricks for efficient delivery of CRISPR genome editing technology into primary cells and cell lines.
Read More
"Technology Dance" Looks Set To Transform the Field of DNA Synthesis
Industry InsightCodexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.
Read More
Decoding the Immune System
Industry InsightOur immune system is incredibly complex. Developing a complete understanding is an enormous undertaking but one to which scientists have been striving in order to advance disease understanding and improve treatments.
Read More
